Yes—TAF is in two phase-3 trials as a standalone agent in HBV, where it is being tested head-to-head vs Viread: HBeAg+ https://www.clinicaltrials.gov/ct2/show/NCT01940471 HBeAg- https://www.clinicaltrials.gov/ct2/show/NCT01940341